All lobbying filings
SPLITOAK STRATEGIES LLC
Lobbying for ALKERMES, INC. · Global biopharmaceutical company
Filing
4th Quarter - Report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Income
$60,000.00
What the client paid this registrant for the period.
Client based in
District of Columbia
Lobbyists on this filing
1
-
SARAH KUEHL EGGEPreviously held: Sarah: 1998-2000 Legislative Assistant to Senator Bob Kerrey; 2001-2012 Senior Budget Analyst for Democratic Staff of the Senate Budget Committee (Kent Conrad); Fall 2011, Deputy Staff Director, Joint Select Committee for Deficit Reduction
Government bodies contacted
1
Bills named in this filing
1
Lobbying activity
1
Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments for substance use disorder and alcohol use disorder; Initiatives to promote the use of relapse prevention post detoxification; Advance the use and funding of FDA-approved medicines to treat serious mental illness in criminal justice and public health settings; H.R. 4030, Treatment Continuity Act of 2025